Ramipril: vozmozhnosti primeneniya pri ishemicheskoy bolezni serdtsa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review considers the potentials for the use of ACE inhibitors in patients with coronary heart disease (CHD). The hemodynamic and neurohumoral effects of the drugs in this group, and features of pharmacokinetics are discussed. The research on one of the drugs of this group - ramipril - is considered in detail. Detailed descriptions of the results of AIRE and HOPE trials as a basis for inclusion of ramipril in the treatment recommendations for patients with acute myocardial infarction and for the secondary prevention of high-risk patients with CHD are presented. Evidence of the efficacy of ramipril in the treatment of myocardial infarction and possible mechanisms to reduction of the risk of complications are presented.

Full Text

Restricted Access

About the authors

L. O Minushkina

References

  1. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease Eur Heart J 2004;25(16):1454-70.
  2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44(3):E1-E211.
  3. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997;95(12):2643-51.
  4. Foster RE, Johnson DB, Barilla F, et al. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction. Am Heart J 1998;136(2):269-75.
  5. Johnson DB, Foster RE, Barilla F, et al. Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction >40 % after acute myocardial infarction. J Am Coll Cardiol 1997; 29(1):49-54.
  6. Van der Ent M, Remme WJ, Bartels GL, et al. Early administration of ramipril in acute myocardial infarction: neurohormonal and hemodynamic effects and tolerability. Cardiology 1997;88(6):548-55.
  7. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997;96(2):442-47.
  8. Sinkovic A. Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction. Wien Klin Wochenschr 2010;122(2):74-8.
  9. Ball SG, Hall AS, How ACE inhibitors reduce death from myocardial infarction: hypotheses from the AIRE study. Acute Infarction Ramipril Efficacy study. Br J Clin Pract 1996;84:31-5.
  10. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342(8875): 821-28.
  11. Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997;18(1):41-51.
  12. Kongstad-Rasmussen O, Blomstrand P, Broqvist M. Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction. Clin Cardiol 1998;21(11):807-11.
  13. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997;349(9064):1493-97.
  14. Vitovec J, Spinarova L. FARIM FARIM -FARmakoterapie po Infarktu Myokardu (Post-Myocardial Infarction Pharmacotherapy Study). Vnitr Lek 2011;57(9):778-84.
  15. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004;141(2): 102-12.
  16. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(2):1-113.
  17. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104(5):522-26.
  18. Teo KK, Mitchell LB, Pogue J, et al. Effect of ramipril in reducing sudden deaths and nonfa-tal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation 2004;110(11):1413-17.
  19. Mann JF, Yi QL, Sleight P, Dagenais GR, et al. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol 2005;63(3):181-87.
  20. Dagenais GR, Pogue J, Teo KK, et al. Impact of ramipril on the circadian periodicity of acute myocardial infarction. Lonn EM, Yusuf S; HOPE Study Investigators. Am J Cardiol 2006;98(6):758-60.
  21. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011; 32(17):2135-42.
  22. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006;114(3):201-08.
  23. Bosch J, Lonn E, Pogue J, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112(9):1339-46.
  24. Chu CS, Cheng KH, Lee KT, et al. Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital. Kaohsiung J Med Sci 2005;21(11):511-16.
  25. Sharpe N The HOPE TIPS: the HOPE study translated into practices. Cardiovasc Drugs Ther 2005;19(3):197-201.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies